Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Novel test identifies lymphoma patients likely to respond to new therapy

22.02.2007
Researchers at the Albert Einstein College of Medicine of Yeshiva University have discovered a genetic signature identifying cases of lymphoma that are uniquely susceptible to a newly developed molecular targeted therapy. As a result, physicians organizing clinical trials of the new therapy will be able to enroll patients who’ll be most likely to benefit from it.

The research was led by Dr. Ari Melnick, assistant professor of developmental & molecular biology and medicine at Einstein, who also developed the new lymphoma therapy. The study appears in the February 20 issue of the Proceedings of the National Academy of Sciences.

Each year more than 60,000 Americans are diagnosed with B cell lymphomas—tumors of cells of the immune system that include Hodgkin’s and non-Hodgkin’s lymphomas. B cells are the immune- system cells that make antibodies. Genetic aberrations can cause B cells to multiply uncontrollably, causing B cell lymphomas.

Dr. Melnick’s study focused on a gene called BCL6. The protein it codes for is a transcriptional repressor, which means that it can shut off the functioning of genes in B cells and other cells of the immune system and prevent them from being expressed. The BCL6 protein is normally produced only during a specific stage of B cell development and is never made again. But deregulation of BCL6 can cause the protein to be produced when it shouldn’t be. The unwelcome presence of the BCL6 protein blocks the expression of important genes that normally protect cells from becoming cancerous. As a result, malignant B-cell lymphomas occur.

Mutations or chromosomal rearrangements that deregulate BCL6 are responsible for many cases of diffuse large B cell lymphoma—an aggressive cancer that accounts for up to 30 percent of newly diagnosed non-Hodgkin’s lymphoma cases. In a 2004 Nature Medicine article, Dr. Melnick and colleagues described a peptide, which they dubbed BPI, that showed promise in treating B-cell lymphomas by specifically blocking the cancer-causing effects of the BCL6 protein. But until now, there has been no way to distinguish between diffuse large B cell lymphomas that are caused by BCL6 deregulation and those cases in which BCL6 is expressed but doesn’t actually drive the cancer.

Dr. Melnick reasoned that those diffuse large B cell lymphomas that are caused by BCL6 deregulation should have a characteristic “signature” in which the genes targeted by the BCL6 protein are either expressed (turned on) or not expressed. The researchers used state-of-the-art genomics technology to analyze a panel of diffuse large B cell lymphoma cell lines. They found a set of 485 BCL6-controlled genes and confirmed that all lymphomas with the BCL6 signature are killed by BPI while lymphomas without the signature are resistant to the therapy.

“Suitable lymphoma patients—those whose tumor cells exhibit this BCL6 signature --will now have access to a potent and specific therapy that is unlikely to cause the side effects associated with chemotherapy drugs,” says Dr. Melnick. “At the same time, lymphoma patients who don’t fit this genetic profile will be spared a drug treatment that would be ineffective for them.”

Other Einstein scientists involved in the study were Jose M. Polo, Leandro Cerchietti, Kenny Ye and John M. Greally. The researchers also included Przemyslaw Juszczynski and Margaret Shipp of the Dana-Farber Cancer Institute and Stefano Monti of the Broad Institute.

Karen Gardner | EurekAlert!
Further information:
http://www.aecom.yu.edu

More articles from Health and Medicine:

nachricht Bioinspired nanoscale drug delivery method developed by WSU, PNNL researchers
10.01.2019 | Washington State University

nachricht How herpesviruses shape the immune system
09.01.2019 | German Center for Infection Research

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Nanocellulose for novel implants: Ears from the 3D-printer

Cellulose obtained from wood has amazing material properties. Empa researchers are now equipping the biodegradable material with additional functionalities to produce implants for cartilage diseases using 3D printing.

It all starts with an ear. Empa researcher Michael Hausmann removes the object shaped like a human ear from the 3D printer and explains:

Im Focus: Elucidating the Atomic Mechanism of Superlubricity

The phenomenon of so-called superlubricity is known, but so far the explanation at the atomic level has been missing: for example, how does extremely low friction occur in bearings? Researchers from the Fraunhofer Institutes IWM and IWS jointly deciphered a universal mechanism of superlubricity for certain diamond-like carbon layers in combination with organic lubricants. Based on this knowledge, it is now possible to formulate design rules for supra lubricating layer-lubricant combinations. The results are presented in an article in Nature Communications, volume 10.

One of the most important prerequisites for sustainable and environmentally friendly mobility is minimizing friction. Research and industry have been dedicated...

Im Focus: Mission completed – EU partners successfully test new technologies for space robots in Morocco

Just in time for Christmas, a Mars-analogue mission in Morocco, coordinated by the Robotics Innovation Center of the German Research Center for Artificial Intelligence (DFKI) as part of the SRC project FACILITATORS, has been successfully completed. SRC, the Strategic Research Cluster on Space Robotics Technologies, is a program of the European Union to support research and development in space technologies. From mid-November to mid-December 2018, a team of more than 30 scientists from 11 countries tested technologies for future exploration of Mars and Moon in the desert of the Maghreb state.

Close to the border with Algeria, the Erfoud region in Morocco – known to tourists for its impressive sand dunes – offered ideal conditions for the four-week...

Im Focus: Programming light on a chip

Research opens doors in photonic quantum information processing, optical signal processing and microwave photonics

Researchers from the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) have developed a new integrated photonics platform that can...

Im Focus: Physicists uncover new competing state of matter in superconducting material

A team of experimentalists at the U.S. Department of Energy's Ames Laboratory and theoreticians at University of Alabama Birmingham discovered a remarkably long-lived new state of matter in an iron pnictide superconductor, which reveals a laser-induced formation of collective behaviors that compete with superconductivity.

"Superconductivity is a strange state of matter, in which the pairing of electrons makes them move faster," said Jigang Wang, Ames Laboratory physicist and...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

11th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Aachen, 3-4 April 2019

14.01.2019 | Event News

ICTM Conference 2019: Digitization emerges as an engineering trend for turbomachinery construction

12.12.2018 | Event News

New Plastics Economy Investor Forum - Meeting Point for Innovations

10.12.2018 | Event News

 
Latest News

Scientists coax proteins to form synthetic structures with method that mimics nature

15.01.2019 | Life Sciences

Next generation photonic memory devices are light-written, ultrafast and energy efficient

15.01.2019 | Information Technology

Viennese scientists develop promising new type of polymers

15.01.2019 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>